Author: "Herrera, Pilar" / Publication Year Range: Last 3 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Herrera, Pilar"' showing total 45 results

Start Over Author "Herrera, Pilar" Publication Year Range Last 3 years

45 results on '"Herrera, Pilar"'

1. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

Author: Pabst, Thomas, Papayannidis, Cristina, Demirkan, Fatih, Doronin, Vadim, Fogliatto, Laura M, Guttke, Christina, Gyan, Emmanuel, Hamad, Nada, Herrera, Pilar, Hultberg, Anna, Jacobs, Julie, Johnson, Amy J, Langlois, Angélique, Ma, Xuewen, Martinelli, Giovanni, Arnan, Montserrat, Müller, Rouven, Nottage, Kerri, Ofran, Yishai, Özcan, Muhit, Samoilova, Olga, Tolbert, Jaszianne A, Trudel, Géralyn C, Xiu, Liang, Vey, Norbert, and Wei, Andrew H
Published: 2023
Full Text: View/download PDF

2. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

Author: Martínez-Cuadrón, David, Megías-Vericat, Juan E., Serrano, Josefina, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, Gil, Cristina, Aguiar, Eliana, Bergua, Juan, López-Lorenzo, José L., Bernal, Teresa, Espadana, Ana, Colorado, Mercedes, Rodríguez-Medina, Carlos, López-Pavía, María, Tormo, Mar, Algarra, Lorenzo, Amigo, María-Luz, Sayas, María J., Labrador, Jorge, Rodríguez-Gutiérrez, Juan I., Benavente, Celina, Costilla-Barriga, Lissette, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Vives, Susana, Herrera, Pilar, García-Belmonte, Daniel, Herráez, María Mar, Vasconcelos Esteves, Graça, Gómez-Roncero, Maria I., Cabello, Ana, Bautista, Guiomar, Balerdi, Amaia, Mariz, José, Boluda, Blanca, Sanz, Miguel Á., and Montesinos, Pau
Published: 2022
Full Text: View/download PDF

3. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Author: Labrador, Jorge, Martínez‐Cuadrón, David, Boluda, Blanca, Serrano, Josefina, Gil, Cristina, Pérez‐Simón, José A., Bernal, Teresa, Bergua, Juan M., Martínez‐López, Joaquín, Rodríguez‐Medina, Carlos, Vidriales, María B., García‐Boyero, Raimundo, Algarra, Lorenzo, Polo, Marta, Sayas, María J., Tormo, Mar, Alonso‐Domínguez, Juan M., Herrera, Pilar, Lavilla, Esperanza, and Ramos, Fernando
Subjects: ACUTE myeloid leukemia, TREATMENT effectiveness, GENETIC disorder diagnosis, MOLECULAR diagnosis, OVERALL survival
Abstract: Background: There are no studies assessing the evolution and patterns of genetic studies performed at diagnosis in acute myeloid leukemia (AML) patients. Such studies could help to identify potential gaps in our present diagnostic practices, especially in the context of increasingly complex procedures and classifications. Methods: The REALMOL study (NCT05541224) evaluated the evolution, patterns, and clinical impact of performing main genetic and molecular studies performed at diagnosis in 7285 adult AML patients included in the PETHEMA AML registry (NCT02607059) between 2000 and 2021. Results: Screening rates increased for all tests across different time periods (2000–2007, 2008–2016, and 2017–2021) and was the most influential factor for NPM1, FLT3‐ITD, and next‐generation sequencing (NGS) determinations: NPM1 testing increased from 28.9% to 72.8% and 95.2% (p <.001), whereas FLT3‐ITD testing increased from 38.1% to 74.1% and 95.9% (p <.0001). NGS testing was not performed between 2000–2007 and only reached 3.5% in 2008–2016, but significantly increased to 72% in 2017–2021 (p <.001). Treatment decision was the most influential factor to perform karyotype (odds ratio [OR], 6.057; 95% confidence interval [CI], 4.702–7.802), and fluorescence in situ hybridation (OR, 2.273; 95% CI, 1.901–2.719) studies. Patients ≥70 years old or with an Eastern Cooperative Oncology Group ≥2 were less likely to undergo these diagnostic procedures. Performing genetic studies were associated with a favorable impact on overall survival, especially in patients who received intensive chemotherapy. Conclusions: This unique study provides relevant information about the evolving landscape of genetic and molecular diagnosis for adult AML patients in real‐world setting, highlighting the increased complexity of genetic diagnosis over the past 2 decades. A retrospective analysis of 7285 cases over 2 decades. This study explores the evolution of diagnostic practices in acute myeloid leukemia patients, highlighting factors influencing test implementation and their association with patient outcomes. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

4. Algunas notas sobre el modo de acción de los verbos psicológicos reflexivos

Author: Morales Herrera, Pilar, primary
Published: 2021
Full Text: View/download PDF

5. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author: Instituto de Salud Carlos III, European Commission, Pérez-Simón, José A. [0000-0003-3616-6101], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Martínez-Cuadrón, David, Megías-Vericat, Juan E., Gil, Cristina, Bernal, Teresa, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Medina, Carlos, Serrano, Josefina, Herrera, Pilar, Pérez-Simón, José A., Sayas, María-José, Bergua, Juan, Lavilla, Esperanza, Amigo, María Luz, Benavente, Celina, López-Lorenzo, José L., Pérez-Encinas, Manuel, Vidriales, Maria Belén, Colorado, Mercedes, Rueda, Beatriz de, García-Boyero, Raimundo, Marini, Sandra, García-Suárez, Julio, López-Pavía, María, Gómez-Roncero, María Isabel, Noriega, Víctor, López, Aurelio, Labrador, Jorge, Cabello, Ana, Sossa, Claudia, Algarra, Lorenzo, Stevenazzi, Mariana, Solana-Altabella, Antonio, Boluda, Blanca, Montesinos, Pau, Instituto de Salud Carlos III, European Commission, Pérez-Simón, José A. [0000-0003-3616-6101], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Martínez-Cuadrón, David, Megías-Vericat, Juan E., Gil, Cristina, Bernal, Teresa, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Medina, Carlos, Serrano, Josefina, Herrera, Pilar, Pérez-Simón, José A., Sayas, María-José, Bergua, Juan, Lavilla, Esperanza, Amigo, María Luz, Benavente, Celina, López-Lorenzo, José L., Pérez-Encinas, Manuel, Vidriales, Maria Belén, Colorado, Mercedes, Rueda, Beatriz de, García-Boyero, Raimundo, Marini, Sandra, García-Suárez, Julio, López-Pavía, María, Gómez-Roncero, María Isabel, Noriega, Víctor, López, Aurelio, Labrador, Jorge, Cabello, Ana, Sossa, Claudia, Algarra, Lorenzo, Stevenazzi, Mariana, Solana-Altabella, Antonio, Boluda, Blanca, and Montesinos, Pau
Abstract: Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.
Published: 2024

6. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author: Universidad de Sevilla. Departamento de Medicina, Instituto de Biomedicina de Sevilla (IBIS), Martínez-Cuadrón, David, Megías-Vericat, Juan E., Gil, Cristina, Bernal, Teresa, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Medina, Carlos, Serrano, Josefina, Herrera, Pilar, Pérez Simón, José Antonio, Universidad de Sevilla. Departamento de Medicina, Instituto de Biomedicina de Sevilla (IBIS), Martínez-Cuadrón, David, Megías-Vericat, Juan E., Gil, Cristina, Bernal, Teresa, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Medina, Carlos, Serrano, Josefina, Herrera, Pilar, and Pérez Simón, José Antonio
Abstract: Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.
Published: 2024

7. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

Author: Onecha, Esther, Ruiz‐Heredia, Yanira, Martínez‐Cuadrón, David, Barragán, Eva, Martínez Sánchez, María Del Pilar, Linares Gómez, María, Rapado, Inmaculada, Perez‐Oteyza, Jaime, Magro, Elena, Herrera, Pilar, Rojas, José Luis, Gorrochategui, Julián, Villoria, Jesús, Boluda, Blanca, Sargas, Claudia, Ballesteros, Joan, Montesinos, Pau, Martínez López, Joaquín, Ayala Díaz, Rosa María, Onecha, Esther, Ruiz‐Heredia, Yanira, Martínez‐Cuadrón, David, Barragán, Eva, Martínez Sánchez, María Del Pilar, Linares Gómez, María, Rapado, Inmaculada, Perez‐Oteyza, Jaime, Magro, Elena, Herrera, Pilar, Rojas, José Luis, Gorrochategui, Julián, Villoria, Jesús, Boluda, Blanca, Sargas, Claudia, Ballesteros, Joan, Montesinos, Pau, Martínez López, Joaquín, and Ayala Díaz, Rosa María
Abstract: Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next-generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most widely used drugs for AML induction therapy, in a cohort of adult patients uniformly treated according to Spanish PETHEMA guidelines. We identified an adverse mutational profile (EZH2, KMT2A, U2AF1 and/or TP53 mutations) that carries a greater risk of death [hazard ratio (HR): 3 29, P < 0 0001]. A high correlation was found between the ex vivo PharmaFlow results and clinical induction response (69%). Clinical correlation analysis showed that the pattern of multiresistance revealed by ex vivo PharmaFlow identified patients with a high risk of death (HR: 2 58). Patients with mutation status also ran a high risk (HR 4 19), and the risk was increased further in patients with both adverse profiles (HR 4 82). We have developed a new score based on NGS and ex vivo drug testing for AML patients that improves upon current prognostic risk stratification and allows clinicians to tailor treatments to minimise drug resistance., Instituto de Salud Carlos III, CRIS against Cancer foundation, Spanish Ministry of Economy and Competitiveness, Depto. de Bioquímica y Biología Molecular, Fac. de Farmacia, TRUE, pub
Published: 2024

8. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

Author: Martínez-López, Joaquín, primary, de la Cruz, Javier, additional, Gil-Manso, Rodrigo, additional, Yuste, Víctor Jiménez, additional, Aspa-Cilleruelo, José María, additional, Escobar, Cristian Escolano, additional, López-Jiménez, Javier, additional, Duarte, Rafael, additional, Yerovi, Cristina Jacome, additional, Hernández-Rivas, José-Ángel, additional, Herráez, Regina, additional, Quiroz-Cervantes, Keina, additional, Bustelos-Rodriguez, Rosalía, additional, Benavente, Celina, additional, Martínez Barranco, Pilar, additional, Bastos Oteiro, Mariana, additional, Alegre, Adrián, additional, Pérez-Oteyza, Jaime, additional, Ruiz, Elena, additional, Marcheco-Pupo, Eriel Alexis, additional, Cedillo, Ángel, additional, de Soto Álvarez, Teresa, additional, García Ramirez, Patricia, additional, Alonso Trillo, Rosalía, additional, Herrera, Pilar, additional, Bengochea Casado, María Luisa, additional, Arroyo Barea, Andrés, additional, Martin De Bustamante, Jose Manuel, additional, Ortiz, Javier, additional, Calbacho Robles, María, additional, and García-Suárez, Julio, additional
Published: 2024
Full Text: View/download PDF

9. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Author: Rojas, F., Longoni, H., Milone, G., Fernández, I., Conciencia, Clínica, Ramirez, R., Canepa, C., Saba, S., Balladares, G., Ventiurini, C., Mariano, R., Negri, P., Prates, M.V., Milone, J., Fazio, P., Gelemur, M., Ciarlo, S., Bezares, F., López, L., García, J. J, Giunta, M., Kruss, M., Lafalse, D., Marquesoni, E., Casale, M.F., Gimenez, A., Brulc, E.B., Perusini, M.A., Palmer, L., Correa, M.E., Jaramillo, F.J., Rosales, J., Sossa, C., Herrera, J.C., Arango, M., Holojda, J., Golos, A., Ejduk, A., Ochrem, B., Małgorzata, G., Waszczuk-Gajda, A., Drozd-Sokolowska, J., Czemerska, M., Paluszewska, M., Zarzycka, E., Masternak, A., Hawrylecka, Dr., Podhoreka, M., Giannopoulos, K., Gromek, T., Oleksiuk, J., Armatys, bA., Helbig, G., Sobas, M., Szczepaniak, A., Rzenno, E., Rodzaj, M., Piatkowska-Jakubas, B., Skret, A., Pluta, A., Barańska, E., Vasconcelos, G., Brioso, J., Nunes, A., Bogalho, I., Espadana, A., Coucelo, M., Marini, S., Azevedo, J., Crisostomo, A.I., Ribeiro, L., Pereira, V., Botelho, A., Mariz, J.M., Guimaraes, J.E., Aguiar, E., Coutinho, J., Noriega, V., García, L., Varela, C., Debén, G., González, M.R., Encinas, M., Bendaña, A., González, S., Bello, J.L., Albors, M., Algarra, L., Romero, J.R., Bermon, J.S., Varo, M.J., López, V., López, E., Mora, C., Amorós, C., Romero, A., Jaramillo, A., Valdez, N., Molina, I., Fernández, A., Sánchez, B., García, A., Castaño, V., López, T., Bernabeu, J., Sánchez, M.J., Fernández, C., Gil, C., Botella, C., Fernández, P., Pacheco, M., Tarín, F., Verdú, J.J., García, M.J., Mellado, A., García, M.C., González, J., Castillo, T., Colado, E., Alonso, S., Recio, I., Cabezudo, M., Davila, J., Rodríguez, M.J., Barez, A., Díaz, B., Prieto, J., Arnan, M., Marín, C., Mansilla, M., Balaberdi, A., Amutio, M.E., del Orbe, R.A., Ancin, I., Ruíz, J.C., Olivalres, M., Gómez, C., gonzález, I., Celis, M., Atutxa, K., Carrascosa, T., Artola, T., Lizuain, M., Rodriguez, J .I., Arce, O., Márquez, J.A., Atuch, J., Marco de Lucas, F., Díez, Z., Dávila, B., Cantalejo, R., Díaz, M., Labrador, J., Serra, F., Hermida, G., Díaz, F.J., de Vicente, P., Álvarez, R., Alonso, C., Bergua, J.M., Ugalde, N., Pardal, E., Saldaña, R., Rodríguez, F., Martín, E., Hermosín, L., Garrastazul, M.P., Marchante, I., Raposo, J.A., Capote, F.J., Colorado, M., Batlle, A., Yañez, L., García, S., González, P., Ocio, E.M., Briz, M., Bermúdez, A., Jiménez, C., Beltrán, S., Montagud, M., Castillo, I., García, R., Gascón, A., Clavel, J., Lancharro, A., Lnares, L., Herráez, M.M., Milena, A., Romero, M.J., Hernández, B., Calle, C., Benegas, R., Bolívar, Dr., Serrano, J., Dorado, F.J., Sánchez, J., Martínez, M.C., Cerveró, C.J., Busto, M.J., Bernal, M., Moratalla, L., Mesa, Z., Jurado, M., De Miguel, D., Santos, A.B., Arbeteta, J., Pérez, E., Caminos, N., Uresandi, N., Argoitiaituart, N., Swen, J., Uranga, A., Olazaba, I., Gainza, E., Romero, P., Gil, E., Palma, A.J., Gómez, K.G., Solé, M., Rodríguez, J.N., Murillo, I.M., Marco, J., Serena, J., Marco, V., Perella, M., Costilla, L., López, J.A., Baena, A., Almagro, P., Hermosilla, M., Esteban, A., Campeny, B.A., Nájera, M.J., Herrra, P., Fernández, R., González, J.D., Torres, L., Jiménez, S., Gómez, M.T., Bilbao, C., Rodríguez, C., Hong, A., Ramos de Laón, Y., Afonso, V., Ramos, F., Fuertes, M., de Cabo, E., Aguilera, C., Megido, M., García, T., Lavilla, E., Varela, M., Ferrero, S., Arias, J., Vizcaya, L., Roldán, A., Vilches, A., Penalva, M.J., Vázquez, J., Calderón, M.T., Matilla, A., Serí, C., Otero, M.J., García, N., Sandoval, E., Franco, C., Flores, R., Bravo, P., López, A., López, J.L., Blas, C., Díez, A., Alonso, J.M., Soto, C., Arenas, A., García, J., Martín, Y., Villafuerte, P.S., Magro, E., Bautista, G., De Laiglesia, A., Rodríguez, G., Solán, L., Chicano, M., Balsalobre, P., Monsalvo, S., Font, P., Carbonell, D., Martínez, C., Humala, K., Kerguelen, A.E., Hernández, D., Gasior, M., Gómez, P., Sánchez, I., Redondo, S., Llorente, L., Bengochea, M., Pérez, J., Sebrango, A., M. santero, Morales, A., Figuera, A., Villafuerte, P., Alegre, A., Fernández, E., Alonso, A., Martínez, M.P., Martínez, J., Cedena, M.T., Moreno, L., De la Fuente, A., García, D., Chamorro, C., Pradillo, V., Martí, E., Sánchez, J.M., Delgado, I., Rosado, B., Velasco, A., Miranda, C., Salvatierra, G., Foncillas, M., Hernández, J.A., Escolano, C., Benabente, C., Martínez, R., Polo, M., Anguita, E., Riaza, R., Amores, G., Requena, M.J., Javier, F., Villaloón, L., Aláez, C., Nistal, S., Navas, B., Andreu, M.A., Herrera, P., López, J., García, M., Moreno, M.J., Queipo, M.P., Hernández, A., Barrios, M., Heiniger, A., Jiménez, A., Contento, A., López, F., Alcalá, M., Lorente, S., González, M., Morales, E.M., Gutierrez, J., Serna, M.J., Beltrán, V., Romera, M., Berenguer, M., MArtínez, A., Tejedor, A., Amigo, M.L., Ortuño, F., Jerez, A., López, O., Moraleda, J.M., Rosique, P., Gómez, J., Garay, M.C., Cerezuela, P., MArtínez, A.B., González, A., Ibáñez, J., Alfaro, M.J., Mateos, M., Goñi, M.A., Araiz, M.A., Gorosquieta, A., Zudaire, M., Viguria, M., Zabala, A., Alvarellos, M., Quispe, I., Sánchez, M.P., Hurtado, G., Pérez, M., Burguete, Y., Areizaga, N., Galicia, T., Rifón, J., Alfonso, A., Prósper, F., Marcos, M., Tamariz, L.E., Riego, V., Manubens, A., Larrayoz, M.J., Calasanz, M.J., Mañú, A., Paiva, B., Vázquez, I., Burgos, L., Pereiro, M., Rodríguez, M., Pastoriza, M.C., Mendez, J.A., Sastre, J.L., Iglesias, M., Ulibarrena, C., Campoy, F., Jaimes, D., Albarrán, B., Solano, J., Silvestre, A., Albo, C., Suarez, S., Loureiro, C., Figueroa, I., Fernández, M.A., Martínez, A., Poderós, C., Vazquez, J., Iglesias, L., Nieto, A., Torrado, T., Martínez, A.M., Amador, M.L., Oubiña, P., Feijó, E., Dios, A., Loyola, I., Roreno, R., Simiele, A., Álvarez, L., Turcu, V., Vidriales, B., Avendaño, A., Chillón, C., González, V., Govantes, J.V., Rubio, S., Tapia, M., Olivier, C., Queizán, J.A., Pérez, O., Vera, J.A., Muñoz, C., rodriguez, A., González, N., Pérez, J.A., Soria, E., I.Espigado, Falantes, J., Montero, I., García, P., Rodríguez, E., Carrillo, E., Caballero, T., García, C., Couto, C., Simón, I., Gómez, M., Aguilar, C., González, B.J., Lakhwani, S., Bienert, A., González, B., Cabello, A., Oliva, A.Y., González, H., Sancho, L., Paricio, M., Perdiguer, L., Solano, F., Lerma, A., Martínez, M.D., Gómez, M.I., Yeguas, A., Montesinos, P., Barragán, E., Sargas, C., Amigo, R., Martinez, D., Boluda, B., Rodríguez, R., Acuña, E., Cano, I., Escrivá, A., Pedreño, M., Navalón, A., Orts, M., Sayas, M.J., Fernández, M.J., Juan, M.L., Gómez, E., Gimeno, M., Donato, E., Cejalvo, M., Tormo, M., Calabuig, M., Navarro, B., Martin, I., Villamont, E., Miralles, A., Lluch, R., Moragues, M., Ruiz, M.A., Benet, C., Valero, M., Linares, M., Collado, R., Orero, M., Ibañez, P., Lis, M.J., Pérez, P.L., Roig, M., López, M., Mena, A.V., Picón, I., Cánovas, V., Palacios, A., Cuello, R., Borrego, J., burgois, M., Cantalapiedra, A., Norberto, O., Angomas, E., Cidoncha, B., Cuevas, L., Robles, D., Mendiazabal, A., Oiartzabal, I., Guinea de Castro, J.M., Montes, C., Carrasco, V., Pérez, A., Moneva, J.J., Olave, M., Bonafonte, E., Mayor, L., Azaceta, G., Palomera, L., Malo, M., Escobar, M.J., Grasa, J.M., De Rueda, B., Aulés, A., Salvador, C., Ansó, V., Iborra, A., Delagado, P., Rubio, A., Stevenazzi, M., Alpire, I., Irigoin, V., Díaz, L., Guillermo, C., Guadagna, R., Grille, S., Oliver, C., Boada, M., Vales, V., Prado, A.I., De los Santos, A.P., Simoes, Catia, Gonzalez, Carmen, Vergez, François, Sarry, Audrey, Bertoli, Sarah, Ariceta, Beñat, Martínez-Cuadrón, David, Bergua, Juan-Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez-Lorenzo, Jose-Luis, Vidriales, Maria-Belen, Chillon, Carmen, Labrador, Jorge, Falantes, Jose-Francisco, Sayas, María-José, Ayala, Rosa, Martinez-Lopez, Joaquin, Villar, Sara, Calasanz, Maria-Jose, Prosper, Felipe, San-Miguel, Jesús F., Sanz, Miguel Á., Récher, Christian, Paiva, Bruno, and Montesinos, Pau
Published: 2024
Full Text: View/download PDF

10. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

Author: Ribera, Josep-Maria, primary, Morgades, Mireia, additional, Garcia-Calduch, Olga, additional, Sirvent, Maialen, additional, Buendia, Buenaventura, additional, Cervera, Marta, additional, Luzardo, Hugo, additional, Hernandez-Rivas, Jesus-Maria, additional, Sitges, Marta, additional, Garcia-Cadenas, Irene, additional, Abrisqueta, Pau, additional, Montesinos, Pau, additional, Bastos-Oreiro, Mariana, additional, De Llano, Maria-Paz Queipo, additional, Bravo, Pilar, additional, Torrent, Anna, additional, Herrera, Pilar, additional, Garcia-Guinon, Antoni, additional, Vall-llovera, Ferran, additional, Serrano, Josefina, additional, Terol, Maria-Jose, additional, Bergua, Juan-Miguel, additional, Garcia-Noblejas, Ana, additional, Barrenetxea, Cristina, additional, Llorente, Laura, additional, Garcia-Belmonte, Daniel, additional, Gimeno, Eva, additional, Cladera, Antonia, additional, Mercadal, Santiago, additional, and Sancho, Juan-Manuel, additional
Published: 2023
Full Text: View/download PDF

11. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Author: Reinoso-Segura, Marta, Caballero-Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Einsele, Hermann, Nahi, Hareth, Granell, Miquel, López-Corral, Lucía, Reguera, Juan L., García-Cadenas, Irene, Gahrton, Gösta, and Pérez-Simón, José A.
Published: 2022
Full Text: View/download PDF

12. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC

Author: Bailén, Rebeca, Pascual-Cascón, María Jesús, Guerreiro, Manuel, López-Corral, Lucía, Chinea, Anabelle, Bermúdez, Arancha, Sampol, Antonia, Heras, Inmaculada, García-Torres, Estefanía, Torres, Melissa, Roca, José Rifón, Herruzo, Beatriz, Sanz, Jaime, Fonseca, Marta, Herrera, Pilar, Colorado, Mercedes, Bento, Leyre, López-Godino, Oriana, Martín-Calvo, Carmen, Fernández-Caldas, Paula, Marcos-Jubilar, María, Sánchez-Ortega, Isabel, Solano, Carlos, Noriega, Víctor, Humala, Karem, Oarbeascoa, Gillen, Díez-Martín, José Luis, and Kwon, Mi
Published: 2022
Full Text: View/download PDF

13. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author: Martínez-Cuadrón, David, primary, Megías-Vericat, Juan E., additional, Gil, Cristina, additional, Bernal, Teresa, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Medina, Carlos, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Simón, José A. Pérez, additional, Sayas, María J., additional, Bergua, Juan, additional, Lavilla-Rubira, Esperanza, additional, Amigo, Maria Luz, additional, Benavente, Celina, additional, Lorenzo, Jose L. López, additional, Pérez-Encinas, Manuel M., additional, Vidriales, María B., additional, Colorado, Mercedes, additional, De Rueda, Beatriz, additional, García-Boyero, Raimundo, additional, Marini, Sandra, additional, García-Suárez, Julio, additional, López-Pavía, María, additional, Gómez-Roncero, Maria I., additional, Noriega, Víctor, additional, López, Aurelio, additional, Labrador, Jorge, additional, Cabello, Ana, additional, Sossa, Claudia, additional, Algarra, Lorenzo, additional, Stevenazzi, Mariana, additional, Solana-Altabella, Antonio, additional, Boluda, Blanca, additional, and Montesinos, Pau, additional
Published: 2023
Full Text: View/download PDF

14. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

Author: Villar, Sara, Ariceta, Benat, Agirre, Xabier, Urribarri, Aura Daniela, Ayala, Rosa, Martinez-Cuadron, David, Miguel Bergua, Juan, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Simoes, Catia, Herrera, Pilar, Jose Calasanz, Maria, Alfonso-Pierola, Ana, Paiva, Bruno, Martinez-Lopez, Joaquin, San Miguel, Jesus F., Prosper, Felipe, Montesinos, Pau, [Villar, Sara] Inst Invest Sanitaria Navarra IDISNA, Clin Univ Navarra, Serv Hematol & Terapia Celular, Pamplona, Spain, [Alfonso-Pierola, Ana] Inst Invest Sanitaria Navarra IDISNA, Clin Univ Navarra, Serv Hematol & Terapia Celular, Pamplona, Spain, [Paiva, Bruno] Inst Invest Sanitaria Navarra IDISNA, Clin Univ Navarra, Serv Hematol & Terapia Celular, Pamplona, Spain, [San Miguel, Jesus F.] Inst Invest Sanitaria Navarra IDISNA, Clin Univ Navarra, Serv Hematol & Terapia Celular, Pamplona, Spain, [Prosper, Felipe] Inst Invest Sanitaria Navarra IDISNA, Clin Univ Navarra, Serv Hematol & Terapia Celular, Pamplona, Spain, [Villar, Sara] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Ariceta, Benat] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Agirre, Xabier] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Jose Calasanz, Maria] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Alfonso-Pierola, Ana] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Paiva, Bruno] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [San Miguel, Jesus F.] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Prosper, Felipe] CIBERONC Ctr Invest Biomed Red Canc, Pamplona, Spain, [Ariceta, Benat] Univ Navarra, Ctr Invest Med Aplicada CIMA Lab Diagnost, Pamplona, Spain, [Jose Calasanz, Maria] Univ Navarra, Ctr Invest Med Aplicada CIMA Lab Diagnost, Pamplona, Spain, [Paiva, Bruno] Univ Navarra, Ctr Invest Med Aplicada CIMA Lab Diagnost, Pamplona, Spain, [Ariceta, Benat] Univ Navarra, CIMA, Program Hematol Oncol, Pamplona, Spain, [Agirre, Xabier] Univ Navarra, CIMA, Program Hematol Oncol, Pamplona, Spain, [Simoes, Catia] Univ Navarra, CIMA, Program Hematol Oncol, Pamplona, Spain, [Urribarri, Aura Daniela] Fdn Miguel Servet, Navarrabiomed, Pamplona, Spain, [Ayala, Rosa] Hosp Univ 12 Octubre, Madrid, Spain, [Martinez, Pilar] Hosp Univ 12 Octubre, Madrid, Spain, [Martinez-Lopez, Joaquin] Hosp Univ 12 Octubre, Madrid, Spain, [Martinez-Cuadron, David] Hosp Univ & Politecn La Fe, Valencia, Spain, [Montesinos, Pau] Hosp Univ & Politecn La Fe, Valencia, Spain, [Miguel Bergua, Juan] Hosp San Pedro Alcantara, Caceres, Spain, [Vives, Susana] ICO Badalona Hosp Germans Trias & Pujol, Badalona, Spain, [Algarra, Lorenzo] Hosp Gen Albacete, Albacete, Spain, [Tormo, Mar] Univ Valencia, Hosp Clin, Valencia, Spain, [Serrano, Josefina] Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain, [Herrera, Pilar] Hosp Univ Ramon y Cajal, Madrid, Spain, CIBERONC, Instituto de Salud Carlos III/Subdireccion General de Investigacion Sanitaria, Fondo de Investigacion en Salud (FIS), and Government of Navarra (Project AGATA)
Subjects: P53, Cancer Research, Progression, biomarkers, Activation, Expression, acute myeloid leukemia, Classification, elderly, Smar1, transcriptomics, B7-h3, Oncology, prognosis, Rna-seq
Abstract: Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with a five-year overall survival rate below 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML patients into different prognostic groups. However, this classification is not validated for elderly patients treated with a non-intensive approach, and its performance may be suboptimal in this context. Indeed, the transcriptomic landscape of AML in the elderly has been less explored and it might help stratify this group of patients. In the current study, we analyzed the transcriptome of 224 AML patients > 65 years-old at diagnosis treated in the Spanish PETHEMA-FLUGAZA clinical trial in order to identify new prognostic biomarkers in this population. We identified a specific transcriptomic signature for high-risk patients with mutated TP53 or complex karyotype, revealing that low expression of B7H3 gene with high expression of BANP gene identifies a subset of high-risk AML patients surviving more than 12 months. This result was further validated in the BEAT AML cohort. This unique signature highlights the potential of transcriptomics to identify prognostic biomarkers in in elderly AML.
Published: 2022

15. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

Author: Martínez-López, Joaquín, primary, De la Cruz, Javier, additional, Gil-Manso, Rodrigo, additional, Alegre, Adrián, additional, Ortiz, Javier, additional, Llamas, Pilar, additional, Martínez, Yolanda, additional, Hernández-Rivas, José-Ángel, additional, González-Gascón, Isabel, additional, Benavente, Celina, additional, Estival Monteliu, Pablo, additional, Jiménez-Yuste, Víctor, additional, Canales, Miguel, additional, Bastos, Mariana, additional, Kwon, Mi, additional, Valenciano, Susana, additional, Callejas-Charavia, Marta, additional, López-Jiménez, Javier, additional, Herrera, Pilar, additional, Duarte, Rafael, additional, Núñez Martín-Buitrago, Lucía, additional, Sanchez Godoy, Pedro, additional, Jacome Yerovi, Cristina, additional, Martínez-Barranco, Pilar, additional, García Roa, María, additional, Escolano Escobar, Cristian, additional, Matilla, Arturo, additional, Rosado Sierra, Belén, additional, Aláez-Usón, María Concepción, additional, Quiroz-Cervantes, Keina, additional, Martínez-Chamorro, Carmen, additional, Pérez-Oteyza, Jaime, additional, Martos-Martinez, Rafael, additional, Herráez, Regina, additional, González-Santillana, Clara, additional, Del Campo, Juan Francisco, additional, Alonso, Arancha, additional, de la Fuente, Adolfo, additional, Pascual, Adriana, additional, Bustelos-Rodriguez, Rosalía, additional, Sebrango, Ana, additional, Ruiz, Elena, additional, Marcheco-Pupo, Eriel Alexis, additional, Grande, Carlos, additional, Cedillo, Ángel, additional, Lumbreras, Carlos, additional, Arroyo Barea, Andrés, additional, Casas-Rojo, José Manuel, additional, Calbacho, Maria, additional, Diez-Martín, José Luis, additional, and García-Suárez, Julio, additional
Published: 2023
Full Text: View/download PDF

16. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

Author: Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, Generalitat de Catalunya, Barba, Pere, Morgades, Mireia, Montesinos, Pau, Gonzalez-Campos, Jose, Torrent, Anna, Gil, Cristina, Bernal, Teresa, Tormo, Mar, Mercadal, Santiago, Novoa, Sandra, García-Cadenas, Irene, Queipo de Llano, M. Paz, Cervera, Marta, Coll, Rosa, Bermudez, Arancha, Amigo, María Luz, Monsalvo, Silvia, Esteve, Jordi, García-Boyero, Raimundo, Novo, Andres, Hernández, Jesús M., Cladera, Antonia, Martínez-Sánchez, Pilar, Serrano, Josefina, Artola, María Teresa, Soria, Beatriz, Abella, Eugènia, Vall-Llovera, Ferran, Bergua, Juan, Herrera, Pilar, Barrios, Daniel, Ribera, Josep-Maria, Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, Generalitat de Catalunya, Barba, Pere, Morgades, Mireia, Montesinos, Pau, Gonzalez-Campos, Jose, Torrent, Anna, Gil, Cristina, Bernal, Teresa, Tormo, Mar, Mercadal, Santiago, Novoa, Sandra, García-Cadenas, Irene, Queipo de Llano, M. Paz, Cervera, Marta, Coll, Rosa, Bermudez, Arancha, Amigo, María Luz, Monsalvo, Silvia, Esteve, Jordi, García-Boyero, Raimundo, Novo, Andres, Hernández, Jesús M., Cladera, Antonia, Martínez-Sánchez, Pilar, Serrano, Josefina, Artola, María Teresa, Soria, Beatriz, Abella, Eugènia, Vall-Llovera, Ferran, Bergua, Juan, Herrera, Pilar, Barrios, Daniel, and Ribera, Josep-Maria
Abstract: Diagnosis and treatment of hematological cancers is usually provided in many healthcare facilities including large but also middle size centers.1 Providing cancer care in local institutions might be advantageous for patients and caregivers in terms of financial burden and quality of life. However, it might carry potential risks derived of the limited experience of smaller centers and differences in accessibility to complex therapies including allogeneic hematopoietic cell transplantation (allo-HCT) and chimeric antigen receptor (CAR) T-cells. These risks might be especially relevant in infrequent cancers as adult acute lymphoblastic leukemia (ALL).
Published: 2023

17. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

Author: Rey-Búa, Beatriz, primary, Cabrero, Mónica, additional, Bento, Leyre, additional, Montoro, Juan, additional, Bastos-Oreiro, Mariana, additional, Parody, Rocío, additional, Yañez, Lucrecia, additional, Lopez-Godino, Oriana, additional, Zanabili, Joud, additional, Herrera, Pilar, additional, Gutierrez, Gonzalo, additional, Perez, Ariadna, additional, Piñana, Jose L., additional, Novelli, Silvana, additional, Cortés, María, additional, Sureda, Ana Maria, additional, Caballero, Dolores, additional, and García-Sancho, Alejandro Martín, additional
Published: 2022
Full Text: View/download PDF

18. Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Author: Simoes, Catia Patricia, primary, Villar, Sara, additional, Ariceta, Beñat, additional, Garcés, Juan-José, additional, Burgos, Leire, additional, Alignani, Diego, additional, Sarai, Sarvide, additional, Martinez-Cuadron, David, additional, Bergua Burgués, Juan Miguel, additional, Vives, Susana, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martinez Sanchez, Pilar, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Ramos, Fernando, additional, Salamero, Olga, additional, Lavilla, Esperanza, additional, Gil, Cristina, additional, Lopez Lorenzo, Jose Luiz, additional, Belén Vidriales, María, additional, Chillón Santos, María Carmen, additional, Labrador, Jorge, additional, Falantes, José F., additional, Sayas, Maria Jose, additional, Ayala, Rosa, additional, Martínez-López, Joaquín, additional, Alfonso-Pierola, Ana, additional, Calasanz, María José, additional, Prosper, Felipe, additional, San-Miguel, Jesús, additional, Sanz, Miguel A., additional, Montesinos, Pau, additional, and Paiva, Bruno, additional
Published: 2022
Full Text: View/download PDF

19. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Author: Boluda, Blanca, primary, Sargas, Claudia, additional, Ayala, Rosa, additional, Larrayoz, Maria Jose, additional, Chillón Santos, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao, Cristina, additional, Prados de La Torre, Esther, additional, Navarro-Vicente, Irene, additional, Martinez-Cuadron, David, additional, Rodríguez-Veiga, Rebeca, additional, Gil, Cristina, additional, Bernal del Castillo, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martinez Sanchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso Dominguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, Maria Luz, additional, Herrera, Pilar, additional, Sayas, Maria Jose, additional, Lavilla, Esperanza, additional, Martínez-López, Joaquín, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Perez-Simon, Jose A., additional, Gómez-Casares, María Teresa, additional, Sánchez-Garcia, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional
Published: 2022
Full Text: View/download PDF

20. Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Author: Labrador, Jorge, primary, Martinez-Cuadron, David, additional, Boluda, Blanca, additional, Serrano, Josefina, additional, Gil, Cristina, additional, Perez-Simon, Jose A., additional, Bernal del Castillo, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Martínez-López, Joaquín, additional, Rodriguez, Carlos, additional, Belén Vidriales, María, additional, García-Boyero, Raimundo, additional, Algarra, Jesús Lorenzo, additional, Polo, Marta, additional, Sayas, Maria Jose, additional, Tormo, Mar, additional, Herrera, Pilar, additional, Lavilla, Esperanza, additional, Ramos, Fernando, additional, Amigo, Maria Luz, additional, Vives, Susana, additional, Sánchez-Garcia, Joaquín, additional, Bilbao, Cristina, additional, Chillón Santos, María Carmen, additional, Larrayoz, Maria Jose, additional, Ayala, Rosa, additional, Barragán, Eva, additional, Sanz, Miguel A., additional, Montesinos, Pau, additional, and Alonso-Dominguez, Juan Manuel, additional
Published: 2022
Full Text: View/download PDF

21. Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Author: Sargas, Claudia, primary, Ayala, Rosa, additional, Larrayoz, Maria Jose, additional, Chillon, Carmen, additional, Carrillo, Estrella, additional, Bilbao, Cristina, additional, Prados de La Torre, Esther, additional, Martinez-Cuadron, David, additional, Rodríguez-Veiga, Rebeca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso Dominguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, Maria Luz, additional, Herrera, Pilar, additional, Sayas, María J., additional, Lavilla, Esperanza, additional, Martínez-López, Joaquín, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Perez-Simon, Jose A., additional, Gómez-Casares, María Teresa, additional, Sánchez-Garcia, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional
Published: 2022
Full Text: View/download PDF

22. Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Author: Suárez, Edwin Uriel, primary, Alonso, Juan Manuel, additional, Boluda, Blanca, additional, Lavilla, Esperanza, additional, Tormo, Mar, additional, Botella, Carmen, additional, Vives, Susana, additional, Rodriguez, Carlos, additional, Serrano, Josefina, additional, Sayas, María José, additional, Martínez Sánchez, Pilar, additional, Ramos, Fernando, additional, Bernal del Castillo, Teresa, additional, Algarra, Lorenzo, additional, Bergua Burgués, Juan Miguel, additional, Pérez-Simón, José, additional, Herrera, Pilar, additional, Barrios-García, Manuel, additional, Noriega-Concepción, Víctor, additional, Raposo-Puglia, Jóse Ángel, additional, Ayala, Rosa, additional, Barragán, Eva, additional, Martinez-Cuadron, David, additional, and Montesinos, Pau, additional
Published: 2022
Full Text: View/download PDF

23. Evolutionary algorithms applied to multi-layered radiative cooling metamaterials

Author: Lezaun Capdevila, Carlos, Jorajuría, Tania, Torres García, Alicia E., Herrera, Pilar, Beruete Díaz, Miguel, Universidad Pública de Navarra. Departamento de Ingeniería Eléctrica, Electrónica y de Comunicación, Nafarroako Unibertsitate Publikoa. Ingeniaritza Elektrikoa, Elektronikoa eta Telekomunikazio Ingeniaritza Saila, and Universidad Pública de Navarra / Nafarroako Unibertsitate Publikoa. Institute of Smart Cities - ISC
Subjects: Multi-layered radiative cooling metamaterials, Genetic algorithms
Abstract: A newly design method for designing multi-layered radiative cooling metamaterials based on genetic algorithms (GAs) is exposed. The developed GA has been tested in three cases, resulting in three different structures that achieve, theoretically under direct sunlight, a net cooling power of 39.96 W/m 2 , 57.78 W/m 2 and 61.77 W/m 2 . Such devices are composed of 9, 15 and 24 layers respectively with a total thickness of less than 4.8 µm in the worst case. By the nature of the method, fewer design experience in metamaterials is needed, as well as it is free-cost, due to the use of analytical calculations for the emissivity of the meta materials instead of a commercial generic electromagnetic solver. Automated design of radiative cooling multi-layered structures and other applications in the infrared range can be further developed with this work. This work has been performed in the frame of the project "Algoritmos EVOlutivos aplicados a dispositivos de enfriamiento radiativo pasivo ultracompactos basados en METAsuperficies (AEVOMETA II), funded by the Government of Navarre.
Published: 2022

24. Design of multi-layered radiative cooling structures using evolutionary algorithms

Author: Lezaun Capdevila, Carlos, Jorajuría, Tania, Torres García, Alicia E., Herrera, Pilar, Beruete Díaz, Miguel, Universidad Pública de Navarra / Nafarroako Unibertsitate Publikoa. Institute of Smart Cities - ISC, Universidad Pública de Navarra. Departamento de Ingeniería Eléctrica y Electrónica, Nafarroako Unibertsitate Publikoa. Ingeniaritza Elektrikoa eta Elektronikoa Saila, and Gobierno de Navarra / Nafarroako Gobernua
Subjects: Metamaterials, Performance evaluation, Prototypes, Evolutionary computation, Genetic algorithms, Cooling
Abstract: In this work we present a novel way to design thinfilm radiative cooling metamaterials based on genetic algorithms. Three simulations with different design constraints have been done, resulting in three structures that achieve 39.96 W/m2 , 57.78 W/m2 and 61.77 W/m2 under direct sunlight, respectively. These structures are shorter than 5 µm of height and are composed of 9, 15 and 24 layers. This design method has the advantages of being automatable, needs fewer design experience in metamaterials and does not rely on commercial simulators. This work opens the path to an easy way of automated design of thin-film multi-layered devices for radiative cooling and other applications in the infrared range. This work has been performed in the frame of the project “Algoritmos EVOlutivos aplicados a dispositivos de enfriamiento radiativo pasivo ultracompactos basados en METAsuperficies” (AEVOMETA II), funded by the Government of Navarre.
Published: 2022

25. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Author: Simoes, Catia, Villar, Sara, Ariceta, Beñat, Garcés, Juan‐José, Burgos, Leire, Alignani, Diego, Sarvide, Sarai, Martínez‐Cuadrón, David, Bergua, Juan‐Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, and Lopez‐Lorenzo, Jose‐Luis
Subjects: ACUTE myeloid leukemia, ACUTE promyelocytic leukemia, SOMATIC mutation
Abstract: In addition to RNAseq, whole-exome sequencing (WES) was performed using molecular barcoding in paired diagnostic-MRD leukaemic cells from 14 patients (6 of them having paired RNAseq and WES data) (Table S1), all of whom achieving CR/MRD+ (Figure 1A). Among the 1346 mutations that either became undetectable or present at MRD, recurrence in 3 or more patients was observed in 48 genes and time points exclusivity were observed in 20 genes (Figure S3). Differential gene expression analysis was performed in I R i using DESeq2 (Methods S1).[12] There was only one gene ( I PIEZO2 i ) differentially expressed between leukaemic cells at diagnosis versus after treatment in patients achieving PR. By contrast, there were 117 differentially expressed genes (adj I p i <0.05, log2FoldChange > |2|) between leukaemic cells at diagnosis vs after treatment in CR/MRD+ patients (Figure S2, Table S2). [Extracted from the article]
Published: 2023
Full Text: View/download PDF

26. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Author: Universidad de Sevilla. Departamento de Medicina, Reinoso-Segura, Marta, Caballero Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Gahrton, Gösta, Pérez Simón, José Antonio, Universidad de Sevilla. Departamento de Medicina, Reinoso-Segura, Marta, Caballero Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Gahrton, Gösta, and Pérez Simón, José Antonio
Abstract: The use of reduced-intensity conditioning (RIC) regimens has decreased the risk of nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). In contrast, disease relapse remains the most frequent cause of treatment failure and death. Owing to both their antimyeloma effect and immunomodulatory properties, novel drugs could improve outcomes after alloSCT. This phase II European Myeloma Network trial was designed to evaluate the combination of alloSCT with novel agents. The study was conducted to evaluate the toxicity and efficacy of RIC intensified with bortezomib (Bz) prior to alloSCT for high-risk (HR) multiple myeloma (MM) patients, as well as the efficacy of post-transplantation maintenance with Bz and lenalidomide (Len). Patients received RIC with Bz on days -9 and -2, fludarabine on days -6 to -4, and melphalan on day -3. Patients who were in complete response (CR) or near CR at day +100 post-transplantation received 6 cycles of Bz every 56 days, and the remaining received Bz, Len, and dexamethasone. Len maintenance was started on day +180 at a dose of 5 mg and continued until relapse or toxicity occurred. Of the 24 patients included, 21 were evaluable on day +100, including 12 in CR, 4 in very good partial response, 3 in partial response, and 2 with relapse or progression. The cumulative incidence (CuI) of relapse was 13.6% (95% confidence interval [CI], 3.2% to 31.3%) at 1 year and 28.5% (95% CI, 11.1% to 48.9%) at 2 years. The CuI of NRM was 21.1% (95% CI, 7.4% to 39.4%) at 2 years. With a median follow-up of 39 months (range, 1 to 67 months), the median event-free survival (EFS) was 29 months, and median overall survival (OS) was not reached. EFS and OS at 3 years were 42.5% (95% CI, 21.9% to 61.7%) and 74.01% (95% CI, 50.9% to 87.5%), respectively. The use of Bz within an RIC regimen allows for a high response rate after alloSCT. Maintenance with Bz and Len is feasible and provides remarkable results in terms of EFS and OS in HR MM pa
Published: 2022

27. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

Author: Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Instituto de Investigación Hospital 12 de Octubre, Ayala Bueno, Rosa, Carreño-Tarragona, Gonzalo, Barragán, Eva, Boluda, Blanca, Larráyoz, María José, Chillón, M. del Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Sanchez-Garcia, Joaquin, Bernal, T., Martínez-Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez-Medina, Carlos, Bergua, Juan, Pérez-Simón, José A., Calbacho, María, Alonso-Domínguez, Juan Manuel, Labrador, Jorge, Tormo, Mar, Amigo, María Luz, Herrera, Pilar, Rapado, Inmaculada, Sargas, Claudia, Vázquez, Iria, Calasanz, Mª Jose, Gómez-Casares, M. T., García-Sanz, Ramón, Sanz, Miguel Ángel, Martínez-López, Joaquín, Montesinos, Pau, Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Instituto de Investigación Hospital 12 de Octubre, Ayala Bueno, Rosa, Carreño-Tarragona, Gonzalo, Barragán, Eva, Boluda, Blanca, Larráyoz, María José, Chillón, M. del Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Sanchez-Garcia, Joaquin, Bernal, T., Martínez-Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez-Medina, Carlos, Bergua, Juan, Pérez-Simón, José A., Calbacho, María, Alonso-Domínguez, Juan Manuel, Labrador, Jorge, Tormo, Mar, Amigo, María Luz, Herrera, Pilar, Rapado, Inmaculada, Sargas, Claudia, Vázquez, Iria, Calasanz, Mª Jose, Gómez-Casares, M. T., García-Sanz, Ramón, Sanz, Miguel Ángel, Martínez-López, Joaquín, and Montesinos, Pau
Abstract: FLT3–ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains controversial. Our study focuses on the prognostic impact of FLT3–ITD and its ratio in a series of 2901 adult patients treated intensively in the pre-FLT3 inhibitor era and reported in the PETHEMA registry. A total of 579 of these patients (20%) harbored FLT3–ITD mutations. In multivariate analyses, patients with an FLT3–ITD allele ratio (AR) of >0.5 showed a lower complete remission (CR rate) and OS (HR 1.47, p = 0.009), while AR > 0.8 was associated with poorer RFS (HR 2.1; p < 0.001). Among NPM1/FLT3–ITD-mutated patients, median OS gradually decreased according to FLT3–ITD status and ratio (34.3 months FLT3–ITD-negative, 25.3 months up to 0.25, 14.5 months up to 0.5, and 10 months ≥ 0.5, p < 0.001). Post-remission allogeneic transplant (allo-HSCT) resulted in better OS and RFS as compared to auto-HSCT in NPM1/FLT3–ITD-mutated AML regardless of pre-established AR cutoff (≤0.5 vs. >0.5). Using the maximally selected log-rank statistics, we established an optimal cutoff of FLT3–ITD AR of 0.44 for OS, and 0.8 for RFS. We analyzed the OS and RFS according to FLT3–ITD status in all patients, and we found that the group of FLT3–ITD-positive patients with AR < 0.44 had similar 5-year OS after allo-HSCT or auto-HSCT (52% and 41%, respectively, p = 0.86), but worse RFS after auto-HSCT (p = 0.01). Among patients with FLT3–ITD AR > 0.44, allo-HSCT was superior to auto-HSCT in terms of OS and RFS. This study provides more evidence for a better characterization of patients with AML harboring FLT3–ITD mutations.
Published: 2022

28. Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia

Author: Centro de Investigación Biomédica en Red Cáncer (España), Martínez-Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, García-Boyero, Raimundo, Rodríguez-Medina, Carlos, Martínez-Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María Luz, Herrera, Pilar, Alonso-Domínguez, Juan Manuel, Bernal, T., Espadana, Ana, Sayas, María-José, Algarra, Lorenzo, Vidriales, Maria Belén, Vasconcelos, Graça, Vives, Susana, Pérez-Encinas, Manuel, López, Aurelio, Noriega, Víctor, García-Fortes, María, Chillón, M. del Carmen, López, Juan A., Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Barragán, Eva, Sanz, Miguel Ángel, Montesinos, Pau, Centro de Investigación Biomédica en Red Cáncer (España), Martínez-Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, García-Boyero, Raimundo, Rodríguez-Medina, Carlos, Martínez-Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María Luz, Herrera, Pilar, Alonso-Domínguez, Juan Manuel, Bernal, T., Espadana, Ana, Sayas, María-José, Algarra, Lorenzo, Vidriales, Maria Belén, Vasconcelos, Graça, Vives, Susana, Pérez-Encinas, Manuel, López, Aurelio, Noriega, Víctor, García-Fortes, María, Chillón, M. del Carmen, López, Juan A., Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Barragán, Eva, Sanz, Miguel Ángel, and Montesinos, Pau
Abstract: This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.
Published: 2022

29. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Author: Janssen Biotech, Celgene, European Myeloma Network, European Society for Blood and Marrow Transplantation, Herrera, Pilar0000-0002-4118-7110, Granell, Miquel [0000-0002-0366-3673], Reinoso-Segura, Marta, Caballero-Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Einsele, Hermann, Nahi, Hareth, Granell, Miquel, López-Corral, Lucía, Reguera-Ortega, Juan Luis, García-Cadenas, Irene, Gahrton, Gösta, Pérez-Simón, José A., Spanish Group of Transplantation, Janssen Biotech, Celgene, European Myeloma Network, European Society for Blood and Marrow Transplantation, Herrera, Pilar0000-0002-4118-7110, Granell, Miquel [0000-0002-0366-3673], Reinoso-Segura, Marta, Caballero-Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Einsele, Hermann, Nahi, Hareth, Granell, Miquel, López-Corral, Lucía, Reguera-Ortega, Juan Luis, García-Cadenas, Irene, Gahrton, Gösta, Pérez-Simón, José A., and Spanish Group of Transplantation
Abstract: The use of reduced-intensity conditioning (RIC) regimens has decreased the risk of nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). In contrast, disease relapse remains the most frequent cause of treatment failure and death. Owing to both their antimyeloma effect and immunomodulatory properties, novel drugs could improve outcomes after alloSCT. This phase II European Myeloma Network trial was designed to evaluate the combination of alloSCT with novel agents. The study was conducted to evaluate the toxicity and efficacy of RIC intensified with bortezomib (Bz) prior to alloSCT for high-risk (HR) multiple myeloma (MM) patients, as well as the efficacy of post-transplantation maintenance with Bz and lenalidomide (Len). Patients received RIC with Bz on days -9 and -2, fludarabine on days -6 to -4, and melphalan on day -3. Patients who were in complete response (CR) or near CR at day +100 post-transplantation received 6 cycles of Bz every 56 days, and the remaining received Bz, Len, and dexamethasone. Len maintenance was started on day +180 at a dose of 5 mg and continued until relapse or toxicity occurred. Of the 24 patients included, 21 were evaluable on day +100, including 12 in CR, 4 in very good partial response, 3 in partial response, and 2 with relapse or progression. The cumulative incidence (CuI) of relapse was 13.6% (95% confidence interval [CI], 3.2% to 31.3%) at 1 year and 28.5% (95% CI, 11.1% to 48.9%) at 2 years. The CuI of NRM was 21.1% (95% CI, 7.4% to 39.4%) at 2 years. With a median follow-up of 39 months (range, 1 to 67 months), the median event-free survival (EFS) was 29 months, and median overall survival (OS) was not reached. EFS and OS at 3 years were 42.5% (95% CI, 21.9% to 61.7%) and 74.01% (95% CI, 50.9% to 87.5%), respectively. The use of Bz within an RIC regimen allows for a high response rate after alloSCT. Maintenance with Bz and Len is feasible and provides remarkable results in terms of EFS and OS in HR MM pa
Published: 2022

30. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

Author: Gutierrez, Antonio, Bento, Leyre, Novelli, Silvana, Martin, Alejandro, Gutierrez, Gonzalo, Queralt Salas, Maria, Bastos-Oreiro, Mariana, Perez, Ariadna, Hernani, Rafael, Cruz Viguria, Maria, Lopez-Godino, Oriana, Montoro, Juan, Pinana, Jose Luis, Ferra, Christelle, Parody, Rocio, Martin, Carmen, Espanol, Ignacio, Yanez, Lucrecia, Rodriguez, Guillermo, Zanabili, Joud, Herrera, Pilar, Varela, Maria Rosario, Sampol, Antonia, Solano, Carlos, Caballero, Dolores, On Behalf Of The Grupo Espanol de Trasplante de Progenitores, Hematopoyeticos Geth And Grupo Espanol de Linfoma Y Trasplante Autologo, and Geltamo
Subjects: CAR-T cell therapy, graft-versus-lymphoma effect, non-relapse mortality, target therapy, acute graft-versus-host disease, allogeneic stem-cell transplantation, mantle cell lymphoma
Abstract: Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
Published: 2022

31. Estudios lingüísticos de jóvenes investigadores (libro completo)

Author: Morales Herrera, Pilar, Peinado Expósito, Pilar, and Ponsoda Alcázar, Yoana
Subjects: Lingüística histórica y comparada
Abstract: Los estudios recogidos en este libro están divididos en: I. Estudios de fonética, gramática y pragmática; II. Sociolingüística; III. Historia de la lengua y estudios clásicos; y IV. Enseñanza del español y otros idiomas como lengua extranjera.
Published: 2021

32. 04 Algunas notas sobre el modo de acción de los verbos psicológicos reflexivos

Author: Morales Herrera, Pilar
Subjects: Español, Fonética, Lengua extranjera, Sociolingüística, Historia de la lengua, Gramática, Pragmática, Estudios clásicos, Enseñanza
Abstract: A continuación, el artículo de Pilar Morales constituye una argumentación de que los verbos psicológicos reflexivos no pueden considerarse estados –como se ha propuesto previamente en la bibliografía–, sino que se trata de predicados de base escalar que denotan eventos de cambio de estado, télicos y dinámicos, cuya estructura eventiva compleja les permite denotar tanto eventos puntuales como durativos.
Published: 2021

33. The Importance of Disease Burden after Induction and Prior to Transplantation in Patients with Acute Myeloid Leukaemia Receiving Allogeneic Transplantation

Author: Nunez-Torron, Claudia, primary, Jimenez Chillon, Carlos, additional, Martin Moro, Fernando, additional, Luna, Alejandro, additional, Saez, Adolfo, additional, Velázquez-Kennedy, Kyra, additional, Marquet Palomanes, Juan, additional, Piris-Villaespesa, Miguel, additional, Garcia-Gutiérrez, Valentín, additional, Chinea, Anabelle, additional, Moreno Jiménez, Gemma, additional, López Jiménez, Javier, additional, and Herrera, Pilar, additional
Published: 2021
Full Text: View/download PDF

34. Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Author: Bailen, Rebeca, primary, Pascual-Cascon, Maria Jesus, additional, Guerreiro, Manuel, additional, López Corral, Lucía, additional, Chinea, Anabelle, additional, Bermúdez, Arancha, additional, Sampol, Antonia, additional, Heras, Inmaculada, additional, García-Torres, Estefanía, additional, Torres, Melissa, additional, Rifon Roca, Jose J., additional, Herruzo, Beatriz, additional, Sanz, Jaime, additional, Fonseca, Marta, additional, Herrera, Pilar, additional, Colorado, Mercedes, additional, Bento, Leyre, additional, López-Godino, Oriana, additional, Martin Calvo, Carmen, additional, Oarbeascoa, Gillen, additional, Diez-Martin, Jose L., additional, and Kwon, Mi, additional
Published: 2021
Full Text: View/download PDF

35. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain

Author: Ribera, Josep-Maria, primary, Morgades, Mireia, additional, Coll, Rosa, additional, Barba, Pere, additional, López-Lorenzo, Jose-Luis, additional, Montesinos, Pau, additional, Foncillas, María-Angeles, additional, Cabrero, Mónica, additional, Gómez-Centurión, Ignacio, additional, Morales, María-Dolores, additional, Varela, María-Rosario, additional, Herrera, Pilar, additional, García-Cadenas, Irene, additional, Calbacho, María, additional, Torrent, Anna, additional, Maluquer, Clara, additional, Calabuig, Marisa, additional, Garcia-Guiñon, Antoni, additional, Bautista, Guiomar, additional, Llorente, Laura, additional, Gil, Cristina, additional, Artola, María-Teresa, additional, González-Campos, José, additional, Fernández-Moreno, Ainhoa, additional, Bárez, Abelardo, additional, Giménez-Pérez, Teresa, additional, Bergua, Juan, additional, Sánchez-Sánchez, María-José, additional, Mateos, María-Carmen, additional, and Piñana, José-Luis, additional
Published: 2021
Full Text: View/download PDF

36. Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Author: Gonzalez, Carmen, Simoes, Catia, Ariceta, Beñat, Martinez-Cuadron, David, Bergua Burgues, Juan Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martinez Sanchez, Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, Gil, Cristina, Lopez Lorenzo, Jose Luiz, Vidriales Vicente, Maria, Chillon, Carmen, Labrador, Jorge, Falantes, Jose Francisco, Sayas Lloris, Maria Jose, Ayala, Rosa, Martinez-Lopez, Joaquin, Villar, Sara, Calasanz, Maria Jose, Prosper, Felipe, San Miguel, Jesus, Sanz, Miguel A., Montesinos, Pau, and Paiva, Bruno
Published: 2023
Full Text: View/download PDF

37. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.

Author: Ribera, Josep-Maria, García, Olga, Buendía-Ureña, Buenaventura, Terol, Maria-José, Vicent, Ana, Vall-Llovera, Ferran, Bergua, Juan, García-Cadenas, Irene, Esteve, Jordi, Ribera, Jordi, Acuña-Cruz, Evelyn, Herrera, Pilar, Hernández-Rivas, Jesus-Maria, Abrisqueta, Pau, González-Campos, José, Rodríguez, Carlos, Bastos-Oreiro, Mariana, Genescà, Eulàlia, Caminos, Nerea, and Queipo de Llano, Maria-Paz
Subjects: HIV infections, BURKITT'S lymphoma
Abstract: This study shows that the clinical and biologic characteristics of adult patients with BL and BLL were similar to those of patients from the BL-IPI cohort. Consequently, the BL-IPI was validated in our series of patients with BL and BLL. Keywords: Burkitt lymphoma; prognosis; International Prognostic Index; validation EN Burkitt lymphoma prognosis International Prognostic Index validation 1993 1996 4 08/22/22 20220801 NES 220801 Chemoimmunotherapy including rituximab and high-dose or infusional chemotherapy constitute the standard treatment for patients with Burkitt's lymphoma (BL) or Burkitt's lymphoma and leukemia (BLL) [[1], [3]]. [Extracted from the article]
Published: 2022
Full Text: View/download PDF

38. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia.

Author: Martínez-Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, García-Boyero, Raimundo, Rodríguez-Medina, Carlos, Martínez-Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María L., Herrera, Pilar, Alonso-Domínguez, Juan M., Bernal, Teresa, Espadana, Ana, Sayas, María J., and Algarra, Lorenzo
Subjects: GENETIC mutation, TIME, HEALTH outcome assessment, RETROSPECTIVE studies, PROTEIN-tyrosine kinase inhibitors, CANCER genes, PROTEIN-tyrosine kinases, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation, SALVAGE therapy, DATA analysis software
Abstract: Simple Summary: Most adult patients with acute myeloid leukemia (AML) relapse after achieving complete remission with chemotherapy; however, there is no standard second-line (salvage) treatment. We retrospectively investigated 404 patients aged ≥18 years with relapsed/refractory (R/R) AML with an FMS-like tyrosine kinase 3 (FLT3) mutation, treated at a PETHEMA (NCT02607059) site between 1998 and 2018. Patients received salvage treatment with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care (n = 80). Complete remission was achieved by 48% of patients who received intensive therapy vs. 19% with non-intensive therapy. Intensive/non-intensive therapy prolonged overall survival significantly compared with supportive therapy. Of evaluable patients, 22% received an allogeneic stem-cell transplant after complete remission. The majority of patients with FLT3-mutated R/R AML received intensive salvage therapy, with the best outcomes being obtained when intensive salvage treatment was combined with stem-cell transplant. This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant. [ABSTRACT FROM AUTHOR]
Published: 2022
Full Text: View/download PDF

39. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.

Author: Palanques-Pastor, Tomás, Megías-Vericat, Juan Eduardo, Martínez, Pilar, López Lorenzo, José Luis, Cornago Navascués, Javier, Rodriguez Macias, Gabriela, Cano, Isabel, Arnan Sangerman, Montserrat, Vidriales Vicente, María Belén, Algarra Algarra, Jesús Lorenzo, Foncillas, María Ángeles, Herrera, Pilar, Botella Prieto, Carmen, Vives, Susana, Figuera Álvarez, Ángela, Cuevas Palomares, Laida, Sobas, Marta, Contento Gonzalo, Alejandro, Cuello García, Rebeca, and Amutio Diez, María Elena
Subjects: ACUTE myeloid leukemia, SARS-CoV-2, TREATMENT effectiveness, ADULTS, PATIENTS' attitudes
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March–May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients. [ABSTRACT FROM AUTHOR]
Published: 2021
Full Text: View/download PDF

40. Prognostic Impact of NPM1and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Author: Suárez, Edwin Uriel, Alonso, Juan Manuel, Boluda, Blanca, Lavilla, Esperanza, Tormo, Mar, Botella, Carmen, Vives, Susana, Rodriguez, Carlos, Serrano, Josefina, Sayas, María José, Martínez Sánchez, Pilar, Ramos, Fernando, Bernal del Castillo, Teresa, Algarra, Lorenzo, Bergua Burgués, Juan Miguel, Pérez-Simón, José, Herrera, Pilar, Barrios-García, Manuel, Noriega-Concepción, Víctor, Raposo-Puglia, Jóse Ángel, Ayala, Rosa, Barragán, Eva, Martinez-Cuadron, David, and Montesinos, Pau
Published: 2022
Full Text: View/download PDF

41. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDHand NPM1Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Author: Boluda, Blanca, Sargas, Claudia, Ayala, Rosa, Larrayoz, Maria Jose, Chillón Santos, María Carmen, Carrillo-Cruz, Estrella, Bilbao, Cristina, Prados de La Torre, Esther, Navarro-Vicente, Irene, Martinez-Cuadron, David, Rodríguez-Veiga, Rebeca, Gil, Cristina, Bernal del Castillo, Teresa, Bergua Burgués, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martinez Sanchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso Dominguez, Juan Manuel, García-Boyero, Raimundo, Amigo, Maria Luz, Herrera, Pilar, Sayas, Maria Jose, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, María José, García-Sanz, Ramón, Perez-Simon, Jose A., Gómez-Casares, María Teresa, Sánchez-Garcia, Joaquín, Barragán, Eva, and Montesinos, Pau
Published: 2022
Full Text: View/download PDF

42. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Author: Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, and Sancho JM
Subjects: Humans, Young Adult, Aged, Middle Aged, Drug Tapering, Feasibility Studies, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Rituximab therapeutic use, Burkitt Lymphoma drug therapy, Burkitt Lymphoma pathology, Leukemia drug therapy, HIV Infections drug therapy
Abstract: High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks of immunochemotherapy according to stage (localized: 1 and 2 non-bulky; advanced: 2 bulky, 3, 4) and age, with dose reduction in patients >55 years old. Dose-intensity of chemotherapy was reduced in patients ≤55 years old after achieving complete metabolic response (CMR). Their outcomes were compared with those of similar patients included in the former BURKIMAB08 trial, in which there was no dose reduction. CMR was attained in 86 of 107 (80%) patients (17/19 in localized stages and 69/88 in advanced stages). Patients from the BURKIMAB14 trial ≤55 years old showed similar overall survival (OS), fewer infections and cytopenias than patients from the BURKIMAB08 trial. Patients >55 years old had a significantly higher treatment- related mortality despite dose reduction of chemotherapy. With a median follow-up of 3.61 years the 4-year OS probability was 73% (range, 63-81%). Age (≤55 vs. >55 years) and stage (localized vs. advanced) had prognostic significance. No significant differences in OS were observed in HIV-positive versus HIV-negative patients. The results of BURKIMAB14 are similar to those of other dose-intensive immunochemotherapy trials. Age >55 years and advanced stage, but not HIV infection, were associated with poor survival. Dose reduction of chemotherapy in young adults in CMR is safe and does not impact outcomes (clinicaltrials gov. Identifier: NCT05049473).
Published: 2024
Full Text: View/download PDF

43. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

Author: Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M, Martínez-Sánchez P, Rodríguez-Medina C, Serrano J, Herrera P, Simón JAP, Sayas MJ, Bergua J, Lavilla-Rubira E, Amigo ML, Benavente C, Lorenzo JLL, Pérez-Encinas MM, Vidriales MB, Colorado M, De Rueda B, García-Boyero R, Marini S, García-Suárez J, López-Pavía M, Gómez-Roncero MI, Noriega V, López A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, and Montesinos P
Subjects: Humans, Middle Aged, Aged, Retrospective Studies, Disease-Free Survival, Cytarabine, Remission Induction, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Hematopoietic Stem Cell Transplantation
Abstract: Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.
Published: 2024
Full Text: View/download PDF

44. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Author: Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, García-Cadenas I, de Llano MPQ, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, and Ribera JM
Published: 2022
Full Text: View/download PDF

45. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.

Author: Gutierrez A, Bento L, Novelli S, Martin A, Gutierrez G, Queralt Salas M, Bastos-Oreiro M, Perez A, Hernani R, Cruz Viguria M, Lopez-Godino O, Montoro J, Piñana JL, Ferra C, Parody R, Martin C, Español I, Yañez L, Rodriguez G, Zanabili J, Herrera P, Varela MR, Sampol A, Solano C, Caballero D, and On Behalf Of The Grupo Español de Trasplante de Progenitores Hematopoyéticos Geth And Grupo Español de Linfoma Y Trasplante Autólogo Geltamo
Abstract: Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
Published: 2022
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

45 results on '"Herrera, Pilar"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources